Showing results (401-410 of 436) with videos related to
Sort By:
Pageof 44
Scientific Reports|April 8, 2021
Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titersNina Lagerqvist, Kimia T Maleki, Jenny Verner-Carlsson, et al.International Journal of Cancer|January 24, 2020
Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screeningAntonio Ponti, Partha Basu, David Ritchie, et al.Nature Communications|June 18, 2021
Multianalyte serology in home-sampled blood enables an unbiased assessment of the immune response against SARS-CoV-2Niclas Roxhed, Annika Bendes, Matilda Dale, et al.Acta Oncologica (Stockholm, Sweden)|April 24, 2007
Nordic biological specimen banks as basis for studies of cancer causes and control--more than 2 million sample donors, 25 million person years and 100,000 prospective cancersEero Pukkala, Aage Andersen, Göran Berglund, et al.Scientific Reports|March 5, 2021
Antibodies to SARS-CoV-2 and risk of past or future sick leaveJoakim Dillner, K Miriam Elfström, Jonas Blomqvist, et al.Nature Reviews. Clinical Oncology|September 2, 2015
HPV-FASTER: broadening the scope for prevention of HPV-related cancerF Xavier Bosch, Claudia Robles, Mireia Díaz, et al.International Journal of Cancer|October 22, 2017
Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I)Matti Lehtinen, Anna Söderlund-Strand, Simopekka Vänskä, et al.International Journal of Cancer|May 31, 2018
Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III)Matti Lehtinen, Tapio Luostarinen, Simopekka Vänskä, et al.Eclinicalmedicine|July 9, 2020
Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countriesSusanne K Kjaer, Mari Nygård, Karin Sundström, et al.The Lancet. Global Health|September 16, 2022
Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trialDeborah Watson-Jones, John Changalucha, Hilary Whitworth, et al.Pageof 44